UBC spinout Aspect Biosystems has been named to Fast Company’s third annual Next Big Things in Tech list, honoring technological breakthroughs that promise to shape the future of industries — from healthcare and security to artificial intelligence and data.
Aspect Biosystems is applying its full-stack tissue therapeutic platform to develop a novel class of cell-based tissue therapeutics that are biologically functional, immune protective, and suitable for surgical implantation.
By replacing, repairing, or supplementing biological function inside the body, these therapeutics have the potential to transform the lives of millions of people living with difficult-to-treat diseases.
Earlier this year, Aspect inked a $75 million deal with Novo Nordisk worth over US$2.6 billion to develop bioprinted tissue therapeutics for diabetes and obesity.
“We’re honored to accept this recognition from Fast Company,” said Tamer Mohamed, CEO and co-founder of Aspect Biosystems.
“Aspect is taking a truly disruptive approach to regenerative medicine and the treatment of challenging diseases with our full-stack tissue therapeutic platform, and we’re excited to continue this work to revolutionize the standard of care for patients around the world.”
Leave a Reply